Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method.
Biomed Chromatogr
; 33(4): e4468, 2019 Apr.
Article
de En
| MEDLINE
| ID: mdl-30549068
ABSTRACT
Olanzapine is an atypical antipsychotic drug from the thienobenzodiazepine family which displays efficacy in patients with schizophrenia and related psychoses. A novel LC/MS method was developed and validated for determination of olanzapine in schizophrenia patients' plasma. A liquid-liquid extraction procedure was carried out using 5 mL diethyl ether-diisopropyl ether mixture (11, v/v). Average recovery of the extraction procedure was 94.8%. Chromatographic separation was performed on reversed-phase C18 column (250 × 2.0 mm, 5 µm) using mixture of deionized water (trifluoro acetic acid 0.1%)-acetonitrile (2080, v/v) as mobile phase at a flow rate of 1 mL/min. Irbesartan was used as internal standart and total run time was 2.5 min. Mass spectrometric analysis were carried out in selective-ion montoring mode, and detected olanzapine at m/z 313.1 and IS at m/z 429.4 in all forms of the ions. The calibration curve of olanzapine was linear in the range 2-300 ng/mL (r2 > 0.9993). The interday and intraday precisions (RSD) were <7.55%, and accuracy was >7.59% (n = 6). The proposed study was successfully validated with respect to the US Food and Drug Administration guidelines.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Schizophrénie
/
Spectrométrie de masse
/
Neuroleptiques
/
Chromatographie en phase liquide
/
Olanzapine
Type d'étude:
Prognostic_studies
Limites:
Adult
/
Female
/
Humans
/
Male
Langue:
En
Journal:
Biomed Chromatogr
Année:
2019
Type de document:
Article
Pays d'affiliation:
Turquie